Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

ClinicalTrials.gov ID: NCT06685835

Public ClinicalTrials.gov record NCT06685835. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - The CEDAR Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.

Study identification

NCT ID
NCT06685835
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Insmed Incorporated
Industry
Enrollment
214 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 16, 2024 (Actual)
Primary completion
Feb 12, 2026 (Actual)
Completion
Jun 8, 2026 (Actual)
Last update posted
Jun 29, 2026

2024 – 2026

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
USA001 Phoenix Arizona 85054-4502 —
USA007 Sacramento California 95815 —
USA026 Coral Gables Florida 33134 —
USA027 Hollywood Florida 33024 —
USA021 Margate Florida 33063 —
USA018 Miami Florida 33125 —
USA025 Ocala Florida 34470 —
USA004 Tampa Florida 33613 —
USA010 Weston Florida 33331 —
USA028 Atlanta Georgia 30329 —
USA011 Sandy Springs Georgia 30328 —
USA003 Plainfield Indiana 46168 —
USA002 Baton Rouge Louisiana 70809-2725 —
USA017 Boston Massachusetts 02115 —
USA012 Detroit Michigan 48201 —
USA024 Fort Gratiot Michigan 48059 —
USA020 Minneapolis Minnesota 55455 —
USA015 St Louis Missouri 63104 —
USA013 Lebanon New Hampshire 03766 —
USA009 Cleveland Ohio 44106-1716 —
USA016 Springfield Ohio 45505 —
USA019 Hershey Pennsylvania 17033-2360 —
USA022 Philadelphia Pennsylvania 19104-5127 —
USA005 Dallas Texas 75230 —
USA023 Dallas Texas 75231-6077 —
USA008 Spokane Washington 99202 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06685835, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 29, 2026 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06685835 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →